UnJungKangMD

PubMed

• Neuron-derived extracellular vesicles to examine brain mTOR target engagement with sirolimus in patients with multiple system atrophy.
  Krishna A Pucha, Thong C Ma, William York, Un Jung Kang, Horacio Kaufmann, Dimitrios Kapogiannis, Jose-Alberto Palma> ;Parkinsonism & Related Disorders. 2023 Oct 1
• 2 citations
  Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
  Yong Hu, Thong C Ma, Stephanie L Alberico, Yunmin Ding, Lingjing Jin, Un Jung Kang> ;Movement Disorders. 2023 Oct 1
• 2 citations
  Defining the molecular identity and morphology ofastrocytes in mouse and human.
  Philip Hasel, Melissa L Cooper, Anne E Marchildon, Uriel A Rufen-Blanchette, Rachel D Kim, Thong C Ma, Un Jung Kang, Moses V Chao, Shane A Liddelow> ;Biorxiv. 2023 Apr 6
• 7 citations
  Learning critically drives parkinsonian motor deficits through imbalanced striatal pathway recruitment.
  Timothy H C Cheung, Yunmin Ding, Xiaoxi Zhuang, Un Jung Kang> ;Proceedings of the National Academy of Sciences of the United States of America. 2023 Mar 21
• 7 citations
  Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson's disease and multiple system atrophy.
  Hash Brown Taha, Simon Hornung, Suman Dutta, Leony Fenwick, Otmane Lahgui, Kathryn Howe, Nour Elabed, Irish Del Rosario, Darice Y Wong, Aline Duarte Folle, Daniela Mar...> ;Translational Neurodegeneration. 2023 Mar 20
• Author Correction: Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson's disease phenotypes.
  Giulietta Maria Riboldi, Marco J Russo, Ling Pan, Kristen Watkins, Un Jung Kang> ;NPJ Parkinson's Disease. 2023 Feb 4
• Aggregation-Seeding Forms of α-Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid.
  Marco J Russo, Karen MacLeod, Jennifer Lamoureux, Russ Lebovitz, Maria Pleshkevich, Claude Steriade, Thomas Wisniewski, Jennifer A Frontera, Un Jung Kang> ;Movement Disorders. 2022 Dec 1
• 8 citations
  Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.
  Charity G Patterson, Elizabeth Joslin, Alexandra B Gil, Wendy Spigle, Todd Nemet, Lana Chahine, Cory L Christiansen, Ed Melanson, Wendy M Kohrt, Martina Mancini, Debor...> ;Trials. 2022 Oct 6
• 6 citations
  Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson's disease phenotypes.
  Giulietta Maria Riboldi, Marco J Russo, Ling Pan, Kristen Watkins, Un Jung Kang> ;NPJ Parkinson's Disease. 2022 Aug 30
• Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
  Un Jung Kang, Ken Nakamura, Xiaoxi Zhuang> ;Neurology. 2022 Aug 9
• Reply to: "Letter on Discussion of Gait Research".
  Nicolaas I Bohnen, Rui M Costa, William T Dauer, Stewart A Factor, Nir Giladi, Mark Hallett, Simon J G Lewis, Alice Nieuwboer, John G Nutt, Kaoru Takakusaki, Un Jung K...> ;Movement Disorders. 2022 Jun 1
• 16 citations
  mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.
  Jose-Alberto Palma, Jose Martinez, Patricio Millar Vernetti, Thong Ma, Miguel A Perez, Judy Zhong, Yingzhi Qian, Suman Dutta, Katherine N Maina, Ibrar Siddique, Gal Bi...> ;Movement Disorders. 2022 Apr 1
• 15 citations
  Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
  Nicolaas I Bohnen, Rui M Costa, William T Dauer, Stewart A Factor, Nir Giladi, Mark Hallett, Simon J G Lewis, Alice Nieuwboer, John G Nutt, Kaoru Takakusaki, Un Jung K...> ;Movement Disorders. 2022 Feb 1
• 3 citations
  Correction to: High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.
  Marco J Russo, Christina D Orru, Luis Concha-Marambio, Simone Giaisi, Bradley R Groveman, Carly M Farris, Bret Holguin, Andrew G Hughson, David-Erick LaFontant, Chelse...> ;Acta Neuropathologica Communications. 2021 Nov 26
• 74 citations
  High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.
  Marco J Russo, Christina D Orru, Luis Concha-Marambio, Simone Giaisi, Bradley R Groveman, Carly M Farris, Bret Holguin, Andrew G Hughson, David-Erick LaFontant, Chelse...> ;Acta Neuropathologica Communications. 2021 Nov 6
• 17 citations
  Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression
  Luis Concha-Marambio, Carly M. Farris, Bret Holguin, Yihua Ma, John Seibyl, Marco J. Russo, Un Jung Kang, Samantha J. Hutten, Kalpana Merchant, Mohammad Shahnawaz, Cla...> ;Movement Disorders. 2021 Jul 8
• 4 citations
  Correction to: α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson’s disease from multiple system atro...
  Suman Dutta, Simon Hornung, Adira Kruayatidee, Katherine N. Maina, Irish Del Rosario, Kimberly C. Paul, Darice Y. Wong, Aline Duarte Folle, Daniela Markovic, Jose-Albe...> ;Acta Neuropathologica. 2021 Jan 1
• 63 citations
  α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy.
  Suman Dutta, Simon Hornung, Adira Kruayatidee, Katherine N Maina, Irish Del Rosario, Kimberly C Paul, Darice Y Wong, Aline Duarte Folle, Daniela Markovic, Jose-Alberto...> ;Acta Neuropathologica. 2021 Sep 1
• 19 citations
  COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?
  Bastiaan R. Bloem, Claudia Trenkwalder, Álvaro Sánchez-Ferro, Lorraine V. Kalia, Roy N. Alcalay, Han Lin Chiang, Un Jung Kang, Christopher G. Goetz, Patrik Brundin, St...> ;Journal of Parkinson's Disease. 2021 Jan 1
• 33 citations
  A rapid α-synuclein seed assay of Parkinson's disease CSF panel shows high diagnostic accuracy.
  Christina D. Orrù, Thong C. Ma, Andrew G. Hughson, Bradley R. Groveman, Ankit Srivastava, Douglas Galasko, Rachel Angers, Patrick Downey, Karen Crawford, Samantha J. H...> ;Annals of Clinical and Translational Neurology. 2021 Feb 1
• 28 citations
  Alterations in the intrinsic properties of striatal cholinergic interneurons after dopamine lesion and chronic L-DOPA.
  Se Joon Choi, Thong C. Ma, Yunmin Ding, T. H. C. Cheung, Neal Joshi, David Sulzer, Eugene V. Mosharov, Un Jung Kang> ;Elife. 2020 Jul 20
• 17 citations
  Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine‐Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme‐Linked Immunosorbent Assay–Base...
  Katerina Melachroinou, Min Suk Kang, Christopher Liong, Sushma Narayan, Najah Levers, Neal Joshi, Katie Kopil, Samantha J. Hutten, Marco A. S. Baptista, Shalini Padman...> ;Movement Disorders. 2020 Jul 11
• 49 citations
  Mitophagy deficiency increases NLRP3 to induce brown fat dysfunction in mice.
  Myoung Seok Ko, Ji Young Yun, In Jeoung Baek, Jung Eun Jang, Jung Jin Hwang, Seung Eun Lee, Seung Ho Heo, David A. Bader, Chul-Ho Lee, Jaeseok Han, Jong Seok Moon, Jae...> ;Autophagy. 2021 May 1
• 78 citations
  Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders
  Stella M. Papa, Patrik Brundin, Victor S.C. Fung, Un Jung Kang, David J. Burn, Carlo Colosimo, Han Lin Chiang, Roy N. Alcalay, Claudia Trenkwalder> ;Movement Disorders Clinical Practice. 2020 May 1
• 110 citations
  Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders.
  Stella M. Papa, Patrik Brundin, Victor S.C. Fung, Un Jung Kang, David J. Burn, Carlo Colosimo, Han Lin Chiang, Roy N. Alcalay, Claudia Trenkwalder> ;Movement Disorders. 2020 May 1
• Join now to see all

Journal Articles

• Axctosidase A activity in Parkinson�s disease  
  Alcalay RN, Wolf P, Levy OA, Kang UJ, Waters C, Fahn S, Ford B, Kuo SH, Vanegas N, Shah H, Liong C, Narayan S, Pauciulo MW, Nichols WC, Gan-Or Z, Rouleau GA, Chung WK..., Neurobiology of Disease; Neurobiol Dis, 1/1/2018
• Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia  
  Lim A, Xia R, Ding Y, Won L, Ray WJ, Hitchcock SA, McGehee D, Neurobiol Dis, 1/1/2015
• Longitudinal follow-up of SWEDD Subjects in PRECEPT study  
  Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang A, Hyson C, Jennings D, and The Parkinson Study Group PRECEPT Investigators, Neurology, 1/1/2014
• Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial  
  Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators, J Parkinsons Dis, 1/1/2014
• The role of DaScan and clinical diagnosis in PD  
  Xie T, Warnke P, Kang UJ, Write Click Neurology, 1/16/2012
• CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion  
  Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, A..., Neurology, 1/6/2012
• Characterization of a Large Group of Individuals with Huntington Disease and Their Relatives Enrolled in the COHORT Study  
  Dorsey ER, the Huntington Study Group COHORT Investigators, PloS ONE, 1/1/2012
• Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2  
  Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER,..., Ann Neurol, 1/1/2012
• Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN�, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia  
  Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group, J Neurol Sci, 1/15/2011
• Serum urate and probability of dopaminergic deficit in early "Parkinson's disease"  
  Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators, Mov Disord, 1/15/2011
• Copy number variation in familial Parkinson disease  
  Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL; PSG-PROGENI and GeneP..., PLoS One, 1/1/2011
• Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts  
  Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators, Mov Disord, 1/1/2011
• Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease  
  Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kiebu..., Mov Disor, 1/15/2010
• Genome-wide association study for onset age in Parkinson disease  
  Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Foroud T; PROGENI Investig..., BMC Med Genet, 1/22/2009
• A Longitudinal Program for Biomarker Development in Parkinson disease: a Feasibility Study  
  Ravina B, Tanner C, DiEuliis D, Eberly S, Flagg E, Galpern WR, FahnS , Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I, and ..., Mov Disord, 1/18/2009
• A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts  
  Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators, Mov Disord, 1/15/2009
• Serum urate as a predictor of clinical and radiographic progression in Parkinson disease  
  Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Ki..., Arch Neurol, 1/1/2008
• Clinical correlates of depressive symptoms in familial Parkinson�s disease  
  Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T, Parkinson�s Study Group � PROGENI Investigators, Mov Disord, 1/1/2008
• The mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson�s Disease  
  The Parkinson Study Group PRECEPT Investigators, Neurology, 1/1/2007
• Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms  
  Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I, the Parkinson Study Group TEMPO and ..., J Neurol Sci, 1/6/2006
• Safety of rasagiline in elderly Parkinson�s disease patients  
  Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, the Parkinson Study Group TEMPO and PRESTO Investigators, Neurology, 1/1/2006
• Mutations in LRRK2 other than G2019S are rare in a North American�based sample of familial Parkinson�s Disease  
  Pankratz N, Pauciulo M, Elsaesser V, Marek D, Halter C, Rudolph A, Shults C, Foroud T, Nichols W, the Parkinson Study Group - PROGENI Investigators, Movement Disorders, 1/1/2006
• Mutations in DJ-1 are rare in familial Parkinson disease  
  Pankratz N, Pauciulo M, Elsaesser V, Marekb D, Halter C, Wojcieszek J, Rudolph A, Shults C, Foroud T, Nichols W, the Parkinson Study Group - PROGENI Investigators, Neuroscience Letters, 1/1/2006
• A Controlled, randomized, delayed-start study of rasagiline in early Parkinson Disease  
  Parkinson Study Group, Arch Neurol, 1/1/2004
• Rating scales for dystonia a multi-center assessment  
  Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, the Dystonia Study Group, Mov Disord, 1/1/2003
• Join now to see all

Books/Book Chapters

• Merritt�s Neurology 
  Chapter: Chapter 80. Tardive dyskinesia 
  Kang UJ, Burke RE, Fahn SEditors: Louis ED, Mayer SA, Rowland LP.Wolters KluwerEdition 13th,2015
• Merritt�s Neurology 
  Chapter: Chapter 83. Parkinson�s disease 
  Fahn S, Kang UJEditors: Louis ED, Mayer SA, Rowland LP.Wolters KluwerEdition 13th,2015
• Parkinson�s Disease 
  Chapter: Chapter 53. Clinical Batteries and Biomarkers in the Diagnosis of Parkinson�s Disease 
  Henchcliff C, Kang UJEditors: Pfeiffer RF, Ebadi M, Wxzolek Z.CRC PressEdition 2nd,2013
• Encyclopedia of Neuroscience 
  Chapter: Gene Therapy: genetically modified cells 
  Kang UJEditors: Squire LR.Oxford: Academic Press2009
• Textbook of Neural Repair and Neurorehabilitation 
  Chapter: Neurotrophic Factor Delivery by Gene Therapy 
  Nakamura K, Kang UJEditors: Selzer ME, Cohen L, Gage FH, Clarke S, Duncan PW.Cambridge University Press2005
• Surgical Treatment of Parkinson�s Disease and other Movement Disorders 
  Chapter: Future Surgical Therapies in Parkinson�s Disease 
  Kang UJ, Chang J, Lee W, Papasian NEditors: Tarsy D, Vitek JL, Lozano AM.Humana Press, Totowa, NJ2002
• Principles of Surgery for Parkinson�s Disease and Movement Disorders 
  Chapter: The potentials of gene therapy for treatment of Parkinson�s Disease 
  Kang UJ, Isacson OEditors: Krauss JK, Jankovic J, Grossman RG.Lippincott, Williams & Wilkins, Philadelphia2001
• Dystonia 3. Advances in Neurology 
  Chapter: The effect of GTP cyclohydrolase I on tyrosine hydroxylase expression: implications in DOPA-responsive dystonia 
  Kang UJ, Bencsics C, Wachtel S, Lew REditors: Fahn S, Marsden CD, DeLong M.Lippincott-Raven Publishers, Philadelphia1998
• Viral Vectors: Gene Therapy and Neuroscience Applications 
  Chapter: Genetic modification of cells with retrovirus vectors for grafting into the central nervous system 
  Kang UJEditors: Kaplitt MG, Loewy AD.Academic Press, San Diego1995
• Merritt's Text Book of Neurology 
  Chapter: Tardive dyskinesia 
  Kang UJ, Fahn SEditors: Rowland LP.Edition 8th,1989
• Dystonia 2. Advances in Neurology 
  Chapter: Natural history and treatment of tardive dystonia 
  Kang UJ, Burke RE, Fahn SEditors: Fahn S, Marsden CD, Calne DB.Raven Press, New York1988
• Facial dyskinesias advances in Neurology 
  Chapter: Tardive dystonia: clinical aspects and treatment 
  Burke RE, Kang UJEditors: Jankovic J, Tolosa E.Raven Press, New York1988
• Join now to see all

Abstracts/Posters

• A Prospective Clinical Cohort and Biorepository of Multiple System Atrophy (MSA)
  Kim J, Gupta D, Liong C, Ma T, Kang UJ, Kuo S-H, Alcalay R, Sklerov M, American Academy of Neurology Annual Meeting, Los Angeles, CA, 1/1/2018
• Modulating SNr neuronal activity in PD and LID
  Hu Y, Ma T, Ding Y, Kang UJ, Gordon Conference on Basal Ganglia, 1/1/2018
• Associative learning contributes to motor impairment after dopamine depletion and is associated with activation of striatopallidal spiny projection neurons
  Cheung T, Ding Y, Kang UJ, Gordon Conference on Basal Ganglia, 1/1/2018
• Parkinson's disease disrupts motor skill learning that requires improvement of a speed-accuracy trade-off
  Kim CY,�Zimnik A, Kang UJ, Mazzoni P, The MDS 21th International Congress of Parkinson�s Disease and Movement Disorders, Vancouver, BC, 1/1/2017
• Motor phenotype classification in moderate to advanced PD: data from the BioFIND study
  Luo L, Andrews HF, Goldman JG, Alcalay RN, Xie T, Tuite P, Henchcliffe C, Hogarth P, Amara A, Frank S, Rudolph A, Casaceli C, Gwinn K, Sutherland M, Kopil C, Vincent L..., The MDS 20th International Congress of Parkinson�s Disease and Movement Disorders, 1/19/2016
• Deep brain stimulation in a case of hemichoreoathetosis with dystonia associated with a developmental venous anomaly and microbleeding in the subthalamic nucleus area
  Xie T, Awad I, Kang U, Warnke P, MDS meeting, 1/1/2013
• L-DOPA-induced dyskinesia is associated with enhanced H2 histamine excitation of striatal cholinergic interneurons
  S. A. Lim, R. Xia, L. Won, Y. Ding, D. S. McGehee, U. J. Kang, Society for Neuroscience, San Diego, CA, 1/1/2013
• Striatal cholinergic ERK activation associated with L-DOPA induced dyskinesia requires D1 receptor activation
  Ding, Y. Won, L. Kang, U, Neuroscience Meeting Planner, New Orleans, LA, 1/1/2012
• The role of M1 muscarinic receptors in L-DOPA induced dyskinesia
  Won, L. Ding, Y. Kang, U, Neuroscience Meeting Planner, New Orleans, LA, 1/1/2012
• The role of D5 dopamine receptors in striatal cholinergic activity associated with L-DOPA induced dyskinesia
  Won, L. Ding, Y. Campioni, M.R. Lim, S.A.O. MeGehee D.S. Kang, U, Neuroscience Meeting Planner, Washington, DC, 1/1/2011
• Activity and dopaminergic medication synergistically produce long lasting motor learning in Parkinson�s disease
  Kang UJ, Auinger P, Parkinson Study Group, Neuroscience Meeting Planner, Washington, DC, 1/1/2011
• Loss of PINK1 decelerates glutamate-induced mitochondrial fission in mouse primary cortical neurons
  Lin, W. Chen, L.White, D. Won, L. Zhuang, X. Kang, U, Neuroscience Meeting Planner, San Diego, CA, 1/1/2010
• Inhibition of dopamine metabolism blocks neurodegeneration in a cytosolic dopamine toxicity mouse model
  Chen L, Xie Z, Ding Y, Won L, Hastings TG, Youdim MBH, Kang UJ , Zhuang X, Neuroscience Meeting Planner, Chicago. IL, 1/1/2009
• DJ-1 is axonal transported and secreted in mouse brains
  Xie Z, Chen L, Cheng H, Ding Y, Won L, Kang UJ , Zhuang X, Neuroscience Meeting Planner, Chicago. IL, 1/1/2009
• PINK1 kinase domain is involved in stability and not localizationProgram No. 545.17.
  Lin W, Simone AJ, Kang UJ, Society for Neuroscience, Washington, DC, 1/1/2008
• Endogenous dopamine causes neurodegeneration in mice
  Chen L, Ding Y, Cagniard B, Chi W, Tian N, Vanlaar AD, Mortimer A, Hastings TG, Kang UJ, Zhuang X, 11th International Congress of Parkinson�s Disease and Movement Disorders, 1/1/2007
• Dysregulation of AChE splicing in acute and chronic models of Parkinson�s disease
  Potashkin J, Loomis P, Ding Y, Jodelka F, Jackolin J, Kang UJ and Meredith G., Society for Neuroscience, 1/1/2007
• P INK1 processing occurs in the mitochondria but localizes and degrades in the cytosol
  Lin W, Kang UJ, Society for Neuroscience, 1/1/2007
• Chronic 3, 4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's Disease
  Ding Y, Restrepo J, Won L, Hwang D-Y, Kim K-S, Kang UJ., Society for Neuroscience, 1/1/2007
• Loss of both DJ-1 and PINK1 leads to early embryonic lethality in mice (675.14/MM29)
  Zhuang X, Chi W, Fleming S, Ding Y, Kang UJ, Chen L, Society for Neuroscience, Washington, DC, 1/1/2006
• Endogenous dopamine causes neurodegeneration in mice (675.15/MM30)
  Chen L, Ding Y, Cagniard B, Chi W, Tian N, Vanlaar AD, Mortimer A, Hastings TG, Kang, UJ, Zhuang X, Society for Neuroscience, Washington, DC, 1/1/2006
• Ubiquitin-proteasome system dysfunction and skeletal muscle atrophy in DJ-1-deficient mice 675.16/MM31)
  Chi W, Chen L, Yang W, Sun X, Kang UJ, Zhuang X, Society for Neuroscience, Washington, DC, 1/1/2006
• Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients: a pilot study using botulinum toxin
  Lo SE, Rosengart AJ, Novakovic RL, Kang UJ, Dalvi A, Frank JI., 9th International Congress of Parkinson�s Disease and Movement Disorders, 1/1/2005
• Chronic delivery of muscimol into the subthalamic nucleus attenuates l-dopa-induced dyskinesia and improves akinesia in hemi-parkinsonian rats Program No. 88.13.
  Ding Y, Rokosik SL, Koh HC, Wright DA, Penn R, Kang UJ, Society for Neuroscience, Washington, DC, 1/1/2005
• ES cell-derived neural precursors, but not ventral mesencephalon-derived neural precursors, maintain the potential to differentiate into dopaminergic neurons after in ...
  Chung S, Hwang M, Kang UJ, Isacson O, Kim K, Society for Neuroscience, Washington, DC, 1/1/2005
• Join now to see all

Lectures

• Aberrant motor learning in PD: learning to move slow? 
  1/30/2018
• Beyond dopamine and DBS in PD therapy: cell-type specific modulation 
  Florence, Italy - 1/14/2018
• Shaking it up 
  HNA Palisades Conference Center, Palisades, NY - 1/8/2018
• Aberrant and beneficial plasticity in PD 
  New York, NY - 1/3/2018
• Basal ganglia plasticity in Parkinson�s disease 
  Boston, MA - 1/20/2017
• Biomarkers for Parkinson�s disease: promises and pitfalls 
  State University of New York, Brooklyn, NY - 1/17/2017
• Cholinergic cells in dyskinesia: Experimental evidence and novel treatments 
  Portland OR - 1/23/2016
• Clinical features of dyskinesia: what, when, and why 
  Portland, OR - 1/22/2016
• Dyskinesia � An ever moving story 
  Portland OR - 1/22/2016
• Basal Ganglia Plasticity in PD Therapy: the good and the bad 
  Columbia University, 2013; Columbia University, 2014 - 1/1/2014
• Adaptive Mechanisms underlying the Short- and Long-Duration Response 
  1/23/2012
• Animal models: what have they taught us about PD? 
  1/19/2011
• Parkinson�s Disease: Practical management issues 
  University of Chicago, Chicago, IL - 1/20/2010
• The molecular mechanisms of beneficial and aberrant plasticity in PD therapy 
  Seoul, Korea - 1/17/2010
• Mechanisms of Parkinson�s Disease Genes 
  Pusan, Korea - 1/1/2009
• Pathophysiological Insights from Recessive Forms of PD 
  Yonsei University, Seoul, Korea - 1/20/2008
• Lessons on Pathogenesis of Parkinson�s Disease from Genetic Studies: Oxidative Stress and DJ-1 
  Albert Einstein College of Medicine, New York, NY - 1/20/2008
• Gene Therapy for Pediatric Neurotransmitter Diseases 
  Washington, D.C. - 1/17/2008
• Parkinon�s Disease 
  Daejeon, Korea - 1/14/2008
• The role of PINK1 in Parkinson�s Disease 
  San Diego - 1/1/2008
• 50 Years of Dopamine in Parkinson�s Disease: a Time to Retire? 
  1/23/2007
• The Promise and Pitfalls of Biomarkers for Diagnosis and Evaluation of Parkinson�s Disease 
  Brown University School of Medicine, Providence, RI - 1/21/2007
• Diagnosis of Parkinson's Disease: Clinical Pearl in Need of Biomarkers 
  University of Chicago, Chicago, IL - 1/20/2007
• Pathophysiology of Parkinson�s Disease: Insights from Genetic Models 
  Northwestern University, Chicago, IL - 1/13/2007
• The genetic Mouse Models of Parkinson�s Disease 
  Korean Advanced Institute of Science and Technology, Daejeon, Korea - 1/3/2007
• Join now to see all